APPENDIX 4. Eating Styles with Evidence of Benefit in Chronic Disease from RCTs or Systematic Review +/-

Meta-analysis (Reference numbers for sources in this appendix are from the **Main** reference list for the module)

| Eating Style | Prevention +/or Risk/Disease Management | Clinical Outcomes (quality of supporting evidence in brackets) |
|--|---|---|
| MEDITERRANEAN | Diabetes | Shown to $\sqrt{}$ incidence of T2D by 19–23%. [High] Greater risk reduction with greater dietary adherence ⁷⁷ [Moderate]. |
| Guideline Inclusion: Canadian Cardiovascular Society CCS re: Dyslipidemia ⁴ and CVD primary prevention ⁵ | | HR for new onset diabetes 0.60 (CI 95% 0.43–0.85) for Mediterranean diet (MedDiet) rich in EVOO* compared to controls on lower-fat diet, in population over age 55 at high CVD risk ⁷⁷ [Moderate]. Improves both glycemic control (may ↓ HbA1c by 0.30–0.47%) and CV risk factors in patients with T2D ^{76,20} [High] and reduces glucose and insulin levels in non-diabetics ²⁰ [High]. |
| Diabetes Canada (overlaid on low glycemic and balanced- carbohydrate intake) | Metabolic Syndrome (MetSy) | High adherence reduces risk factors for incidence of MetSy ⁷⁸ [High]. Reversion of MetSy (HR 1.35 standard low fat diet vs. MedDiet with olive oil 95% Cl 1.15–1.58, $p < 0.001$) in population at high CVD risk over age 55^{79} [Moderate]. |
| | Cardiovascular Disease (CVD) benefit | |
| | Cognitive Health/Function | Mostly small effect sizes for improvements in some cognitive domains (e.g., executive function, memory, language) ⁸¹ [Moderate]. Tiny improvements on MMSE scores with non-significant reduced incidence of MCI on those at high CVD risk ⁸² [Moderate]. Positive effects on cognitive health found particularly with high adherence and with EVOO/nut rich MedDiet but more research needed ⁹ [Moderate] Higher adherence associated with less cognitive decline but effect sizes were very small across |
| | Alzheimer's disease/ | studies ⁷² [Moderate]. Higher adherence associated with lower risk but very small effect sizes in AD and |
| | dementia | cognitive decline – evidence for benefit re: dementia inconsistent 72 [Moderate]. |
| | Cancer | Highest adherence results in significantly lower risk: All cause cancer mortality RR 0.87. In survivors, highest adherence showed reduction in mortality but not cancer Cancers: Breast RR 0.93 Prostate RR 0.96 Colorectal RR 0.83 Gastric RR 0.73 Liver, pancreatic RR 0.58, 0.48 respectively ⁸³ [Moderate]. |
| DASH Guideline Inclusion: CCS as above Heart and Stroke Foundation Hypertension Canada Diabetes Canada | Hypertension | recurrence ⁸³ Significant ↓ SBP ~ 7 mmHg (95% CI: 8.2–5.2) and DBP ~3.5 mmHg (95% CI: 4.29–2.79) with or without weight loss ⁸⁹ [High]. Greater reductions with higher potassium/lower sodium intakes and when restricted energy prescribed ⁸⁴ [High]. |
| | CVD risk reduction | Adherence significantly improves multiple CV risk factors beyond simply $\sqrt{}$ in BP ⁸⁵ [High]. High adherence (high DASH scores) = $\sqrt{}$ in CVD by 20% pooled relative risk (RR 0.80, 95% CI [0.77–0.84]) compared to low DASH score ^{86,87} [Moderate to High] with ~13% predicted reduction in 10-yr Framingham risk score for CV events. ⁸⁵ |
| | Cognitive health, Alzheimer's disease | Mixed results—some positive effects on cognitive health found but more research needed ⁹ [Moderate]. Higher adherence associated with less cognitive decline and lower risk of AD but effect sizes very small ⁷² [Moderate]. |
| | Diabetes | High DASH score = pooled relative risk Ψ for incident diabetes of 18–20% compared to low DASH score ^{86,88} [Moderate to High]. |
| MIND | Cognitive Health, Alzheimer's Disease | Lower risk of AD as with MedDiet and DASH but the "strongest associations observed for the MIND diet" [Moderate]. Positive effects on cognitive health found but more research needed [Moderate]. |
| PORTFOLIO | Cardiovascular disease risk | Four dietary elements of Portfolio overlaid on NCEP-Step II** (≤ 30% total fat, < 7 saturated fat, < 200 mg/day cholesterol); ↓ LDL-C, TC, TG, non-HDL-C and apoB |
| Guideline Inclusion: CCS as above | | [High]; improvements in HDL-C, SBP, DBP, CRP, with ↓ estimated 10-yr risk CHD by 13% ²⁴ [Moderate]. Health Canada recognises the health claims of the individual components of the |
| Diabetes Canada | | Portfolio Diet (such as soy protein, dietary fibre, plant sterols) for lowering cholesterol and/or reducing cardiovascular disease risk. ⁸⁹⁻⁹¹ |
| VEGETARIAN & VEGAN | Ischemic heart disease (IHD) and cancer | Vegetarian– reduction in IHD by 25% (RR 0.75, 95% CI 0.68 to 0.82) and ↓ incidence cancer (RR 0.92, 95% CI [0.87-0.98]) [High] compared to omnivore diet; |
| Guideline Inclusion: CCS as above | and cancer | but not significant for overall mortality or other cardiovascular and cerebrovascular diseases. 82 Vegan style- promising but limited amount of evidence to date for Ψ incidence of |
| Diabetes Canada *EVOO = extra virgin olive | oil; **National Cholesterol Ed | cancer ⁸² [High]. ucation Program Step II dietary plan |
| HR = hazard ratio: CI = confidence interval; RR = relative risk; RRR = elative risk reduction | | |

© The Foundation for Medical Practice Education, www.fmpe.org

May 2020 21

